An Open-label, Multicenter, Follow-up Study to Evaluate the Safety and Efficacy of Levetiracetam (LEV) (Oral Tablets of 166, 250 or 500 mg b.i.d.), at Individualized Doses up to a Maximum of 4000 mg/Day (or 80 mg/kg/Day for Children and Adolescents Less Than 50 kg), in Children (≥ 4 Years Old), Adolescents and Adults Suffering From Primary Generalized Seizures
Phase of Trial: Phase III
Latest Information Update: 31 Mar 2015
At a glance
- Drugs Levetiracetam (Primary)
- Indications Generalised seizures
- Focus Therapeutic Use
- Sponsors UCB Pharma Inc
- 10 Aug 2007 Status changed from in progress to completed.
- 05 Nov 2005 New trial record.